Datapoint: Alvotech Aims to Get Humira Biosimilar to Market Sooner With Lawsuit
May 17
Though Humira biosimilars are set to launch in the U.S. in 2023, biopharmaceutical manufacturer Alvotech is aiming to get its biosim, AVT02, to market faster via a federal lawsuit, per a May 11 press release. Alvotech says AbbVie engaged in “inequitable conduct” to gain its Humira patents, among other allegations centered around the drugmaker’s attempt to “overwhelm” the company with legal issues and create a “wrongful monopoly.” For the treatment of rheumatoid arthritis, the Humira pen holds covered or better status for 70% of all insured lives under the pharmacy benefit. It is classified as a specialty drug for 29.8% of covered lives.
SOURCE: MMIT Analytics, as of 5/12/21
Meet Our Reporters
-
Lauren Flynn Kelly Executive Editor, AIS Health, and Managing Editor, Radar on Medicare Advantage
View Lauren Flynn Kelly's Profile -
Angela Maas Managing Editor, Radar on Specialty Pharmacy and Spotlight on Market Access
View Angela Maas's Profile -
Leslie Small Managing Editor, Health Plan Weekly and Radar on Drug Benefits
View Leslie Small's Profile -
Peter Johnson Reporter, Health Plan Weekly and Radar on Drug Benefits
View Peter Johnson's Profile -
Tim Casey Reporter, Health Plan Weekly and Radar on Drug Benefits
View Tim Casey's Profile -
Carina Belles Reporter, Radar on Medicare Advantage and Spotlight on Market Access
View Carina Belles's Profile -
Jinghong Chen Reporter, Health Plan Weekly and Radar on Drug Benefits
View Jinghong Chen's Profile
